Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Theralase TechnologiesTLTFF -1.69%50 Days Sales Outstanding is 1.17 as of Jun. 2026, which is 99% below its 10-year median of 95.63. GuruFocus rates TLTFF with a GF Score™ of 50/100 and a GF Value™ of $0.14 (Fairly Valued). The stock has 3 warning signs investors should review. Among 810 Medical Devices & Instruments companies, Theralase Technologies ranks better than 96.05% on this metric.
The historical rank and industry rank for Theralase Technologies's Days Sales Outstanding or its related term are showing as below:
TLTFF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.67 Med: 95.63 Max: 257.15
Current: 19.09
During the past 13 years, Theralase Technologies's highest Days Sales Outstanding was 257.15. The lowest was 0.67. And the median was 95.63.
TLTFF's Days Sales Outstanding is ranked better than 96.05% of 810
companies
in the Medical Devices & Instruments industry
Industry Median: 65.25
vs TLTFF: 19.09
Theralase Technologies's Days Sales Outstanding
declined
from Jun. 2025 (43.64) to Jun. 2026 (1.17).
Theralase Technologies (OTCPK:TLTFF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Theralase Technologies Days Sales Outstanding Related Terms
Theralase Technologies Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Theralase Technologies's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies Days Sales Outstanding Chart
TLTFF vs ABT, SYK, MDT: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Theralase Technologies's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's Days Sales Outstanding falls into.
Theralase Technologies Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies (TLTFF) has a Days Sales Outstanding of 1.17 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Theralase Technologies and its competitors. This is 99% below median its historical median of 95.63. Over the past decade, Theralase Technologies' Days Sales Outstanding has ranged from 0.67 to 257.15. According to the industry distribution chart, Theralase Technologies ranks #32 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 4%.
Is Theralase Technologies' Days Sales Outstanding too high?
Theralase Technologies' current Days Sales Outstanding of 1.17 is 99% below median its 10-year median of 95.63. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 257.15. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.25. Theralase Technologies' value of 1.17 is 98.2% below this industry median. Based on the distribution chart, Theralase Technologies ranks #32 out of 810 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Theralase Technologies has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' Days Sales Outstanding compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theralase Technologies ranks #32 out of 810 companies for Days Sales Outstanding. This places Theralase Technologies in the top 4% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 65.25. Theralase Technologies' value of 1.17 is 98.2% below this benchmark. Historically, Theralase Technologies' own Days Sales Outstanding has ranged from 0.67 to 257.15 over the past decade. While the company's 10-year median is 95.63 vs. the industry median of 65.25, Theralase Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.25, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theralase Technologies's current Days Sales Outstanding of 1.17 is 98.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Theralase Technologies and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theralase Technologies's current Days Sales Outstanding is 1.17, which is 99% below median its own 10-year median of 95.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.14, compared to a current price of $0.13 — trading 4.7% below its estimated fair value. The current Days Sales Outstanding is 1.17, which is 99% below median its 10-year median of 95.63 and 98.2% below the Medical Devices & Instruments industry median of 65.25. Theralase Technologies' overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current Days Sales Outstanding is 1.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TLTFF) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be undervalued.
The current stock price of $0.13 is trading 4.7% below its estimated GF Value™ of $0.14.
GuruFocus considers Theralase Technologies to be Fairly Valued.
Key valuation signals for TLTFF:
Days Sales Outstanding: 1.17 (99% below median its 10-year median of 95.63)
GF Value™: $0.14 vs. price of $0.13 (4.7% below fair value)
Industry Position: 98.2% below the Medical Devices & Instruments median (#32 of 810)
No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
50GF Score
Get the complete analysis for TLTFF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLTFF has been successfully added to your 
